

# Ines Pires da Silva

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8876028/publications.pdf>

Version: 2024-02-01

17  
papers

1,354  
citations

932766

10  
h-index

1125271

13  
g-index

17  
all docs

17  
docs citations

17  
times ranked

2931  
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. <i>Cancer Cell</i> , 2019, 35, 238-255.e6.	7.7	547
2	Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade. <i>Cancer Immunology Research</i> , 2014, 2, 410-422.	1.6	322
3	Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. <i>Cancer</i> , 2020, 126, 86-97.	2.0	113
4	Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. <i>Cancer</i> , 2015, 121, 51-59.	2.0	92
5	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <i>BRAF</i> -Mutant Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 1272-1279.	3.2	57
6	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1068-1080.	0.8	43
7	Comprehensive analysis of cutaneous and uveal melanoma liver metastases. , 2020, 8, e001501.		40
8	Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 553-563.	1.5	28
9	Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials. <i>Clinical Cancer Research</i> , 2019, 25, 3247-3258.	3.2	27
10	Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10005-10005.	0.8	26
11	Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy. <i>Journal of Translational Medicine</i> , 2014, 12, 342.	1.8	24
12	Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. , 2022, 10, e004771.		16
13	Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 + Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. <i>Cancers</i> , 2021, 13, 3186.	1.7	11
14	Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. , 2022, 10, e004610.		6
15	Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas. <i>British Journal of Cancer</i> , 2018, 119, 661-662.	2.9	1
16	Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. <i>European Journal of Cancer</i> , 2021, 153, 8-15.	1.3	1
17	Understanding the Tumour Immune Microenvironment (TIME) at different sites of MELANOMA Metastases (METS). <i>Pathology</i> , 2020, 52, S118.	0.3	0